generate and maintain the correct number of cells is a fundamental problem in biology. In principle, tissue turnover can occur by the differentiation of stem cells, as is well documented for blood, skin and intestine, or by the duplication of existing differentiated cells. Recent work on adult stem cells has highlighted their potential contribution to organ maintenance and repair. However, the extent to which stem cells actually participate in these processes in vivo is not clear. Here we introduce a method for genetic lineage tracing to determine the contribution of stem cells to a tissue of interest. We focus on pancreatic b-cells, whose postnatal origins remain controversial. Our analysis shows that pre-existing b-cells, rather than pluripotent stem cells, are the major source of new b-cells during adult life and after pancreatectomy in mice. These results suggest that terminally differentiated b-cells retain a significant proliferative capacity in vivo and cast doubt on the idea that adult stem cells have a significant role in b-cell replenishment.
The literature on pancreatic b-cells and islets of Langerhans is replete with studies suggesting various mechanisms for b-cell homeostasis and regenerative repair. Early studies on patterns of [ 3 H]thymidine incorporation indicated that adult pancreatic endocrine cells belong to a class of tissues that could be maintained by the self-duplication of differentiated cells [1] [2] [3] . More recent immunohistochemical observations suggest a stem-cell origin for islet cells, including insulin-expressing b-cells 4 . It has been proposed that these adult pancreatic stem or progenitor cells reside in the epithelium of pancreatic ducts 5, 6 , inside islets 7 or in the bone marrow 8 . Others have suggested that b-cells form in the adult by transdifferentiation of pancreatic acinar cells 9 , islet cells that express hormones other than insulin 10 , or splenocytes 11 . In addition to explaining the formation of new b-cells within existing islets, it has also been suggested that whole new islets form (islet neogenesis) by clustering of new b-cells that are derived from stem cells 5, 12, 13 . However, all of these models and suggestions are, for the most part, based on the interpretation of static histological data rather than direct lineage analysis 14 . We developed a simple method for distinguishing stem-cellderived b-cells from the progeny of pre-existing b-cells. Fully differentiated b-cells, defined here as post-natal cells transcribing the insulin gene, are heritably labelled in transgenic mice with a tamoxifen-inducible Cre/lox system ('pulse'). The label is the expression of the human alkaline phosphatase protein, which can be detected by a histochemical stain. After a long period, during which turnover occurs ('chase'), b-cells are examined for the presence of the label. Cells generated after the pulse are labelled if and only if they are the progeny of pre-existing (labelled) b-cells; new b-cells derived from any non-b source, including stem cells, are not labelled. Different models of b-cell dynamics have distinct predictions regarding the frequency and distribution of labelled b-cells within pancreatic islets after a chase period (Fig. 1a) . New islets derived entirely from stem or progenitor cells-that is, cells not yet transcribing the insulin gene-would not contain labelled b-cells. In addition, if stem cells replenish b-cells within existing islets, the frequency of labelled b-cells should gradually decrease. By contrast, if new b-cells are derived by self-duplication, the frequency of labelled b-cells within islets should remain constant.
We generated a transgenic mouse strain in which the insulin promoter 15 drives the expression of tamoxifen-dependent Cre recombinase 16 (RIP-CreER). In this strain, the Cre-oestrogenreceptor (ER) fusion gene is expressed only in pancreatic b-cells, but the CreER protein is excluded from the cell nucleus. Tamoxifen injection results in a rapid and transient (about 48 h (ref. 17)) nuclear translocation of the CreER protein, which permits Cremediated recombination. As a readout for Cre activity we used a reporter strain (Z/AP) 18 in which Cre-mediated removal of a stop sequence results in the constitutive and heritable expression of the gene encoding human placental alkaline phosphatase (HPAP) (Fig. 1b) . Thus, a pulse of tamoxifen to bigenic RIP-CreER;Z/AP mice leads to HPAP expression in insulin-expressing cells present at the time of injection, as well as their progeny.
Control experiments with RIP-CreER;Z/AP mice were per- formed to assess the specificity of labelling after tamoxifen injection. HPAP þ cells are found only within islets (Fig. 2a) ; ducts, acini and blood vessels are not labelled (Fig. 2a) . Double immunofluorescent analysis confirmed that ductal and acinar cells (detected by the DBA (Dolichos biflorus agglutinin) lectin and expressing amylase, respectively) do not express HPAP (Fig. 2c) . Within islets, every HPAP þ cell (n . 1,000) expresses insulin (Fig. 2b) . Non-b islet cells (those expressing glucagon, somatostatin or pancreatic polypeptide) were all HPAP 2 , as would be expected from an insulin-promoter-driven transgene (Fig. 2c) . The frequency of HPAP þ cells depended on the tamoxifen dose (Fig. 2d) . Thus, tamoxifen injection leads to a highly specific labelling of only differentiated b-cells (cells transcribing the insulin gene and positive for insulin by immunohistochemistry).
We injected tamoxifen into 24 RIP-CreER;Z/AP mice at 6-8 weeks of age, using a protocol (five injections of 4 mg tamoxifen) that resulted in HPAP expression in about 30% of b-cells. Eight mice were killed 2 days after the last injection (the pulse group) and the remaining 16 mice were killed 2.5 (n ¼ 1), 4 (n ¼ 2), 6 (n ¼ 5), 9 (n ¼ 4) or 12 (n ¼ 4) months later (the chase groups). Note that the 12-month time point represents about one-half of a mouse's lifespan. Sections of the pancreas were stained for insulin to identify b-cells and for HPAP to identify the cells that transcribed the insulin gene at time 0 (the pulse) and their daughters (see Fig. 1 ).
No new islets are formed during adult life
To identify whether entirely new islets were generated during the chase period, we compared the number of islets that contained labelled b-cells in the pulse and chase. Islets derived from stem cells (cells not expressing insulin at the time of pulse) would be completely HPAP 2 in the chase pancreases. All islets analysed (n ¼ 485 for the pulse group, n ¼ 744 for the chase group; islet defined as a group of more than 10 b-cells) contained numerous HPAP þ b-cells. The finding that all islets in the chased mice contained b-cells that were present at the time of tamoxifen injection (or the progeny of such cells; Fig. 3a -c, h) suggests that no new islets are formed by stem or progenitor cells during adult life.
Given this unexpected result we extended our analysis to small, scattered clusters of 1-10 b-cells. The cells in these structures are often interpreted as newly formed, stem-cell-derived b-cells caught in the process of coalescing into larger or mature islets 9, [19] [20] [21] [22] [23] . Such a model predicts that clusters found after a long chase should contain only HPAP 2 cells. In the pulse group, 77.8^8.4% of the small clusters analysed (n ¼ 1,268) contained HPAP þ b-cells, a frequency that was expected given the small size of the clusters and the efficiency of tamoxifen-dependent labelling. In the chase group, 81.8^10.9% of the clusters analysed (n ¼ 1,423) contained HPAP þ b-cells (Fig. 3d-h ). Thus, there was no evidence that new clusters are generated from non-b-cells over the course of 12 months. We conclude, contrary to the commonly held view, that small clusters of b-cells do not represent stem-cell-derived islets. Rather, they might represent static mini-islets and/or disintegrating old islets. Taken together, these results point to the conclusion that no new islets are formed by stem or progenitor cells during adult life in the mouse (ruling out model 1 in Fig. 1a) . The islets present in an old or middle-aged mouse are derived from islets that were present in 'teenage life' (2 months of age). Fig. 1a) .
A trivial explanation to these results would be that very little b-cell turnover occurred during the chase. In such a model, new stem-cell-derived b-cells, even though HPAP 2 , might escape detection because of their low rate of formation. On the contrary, fluorescence-activated cell sorting analysis of dissociated mouse pancreases shows that the absolute number of b-cells increases about 6.5-fold between 3 and 12 months of age ((3.3^0.87) £ 10 5 for 3-month-old mice, n ¼ 5; (2.2^0.9) £ 10 6 for 10-12-monthold mice, n ¼ 4) (Fig. 4) . This means that at least 85% of b-cells present at 12 months of age were formed during the previous 9 months. Taking into account a conservative estimation of t 1/2 ¼ 3 months for adult rodent b-cells 13 , we estimate that 98% of b-cells present in an animal chased for 9 months were born after the pulse. A 'static' interpretation of the pulse-chase results is therefore untenable and we conclude that new b-cells are generated in the adult mouse primarily by the replication of pre-existing b-cells.
b-cell regeneration
Although the above experiments do not provide any evidence for the existence of stem or progenitor cells in the normal growth and maintenance of b-cells, it is possible that stem or progenitor cells do participate in other circumstances. For instance, an emerging concept in the field of adult stem cells is that of facultative stem cells, namely cells that acquire a stem cell character only after stimulation 24, 25 . In the pancreas, such cells have been proposed to reside in ducts, acini or inside islets 4 . After injury, these cells are thought to first proliferate, then differentiate into b-cells and migrate to form new islets or replenish existing islets. To test this idea we used partial pancreatectomy (Px), an injury model in which regeneration has previously been documented 4, 5, 12, [26] [27] [28] [29] . We first verified that Px did indeed result in the generation of new b-cells. Bromodeoxyuridine (BrdU) was administered for 1 week to mice that had undergone partial (70%) Px or had been sham operated. In agreement with previous reports 5, 26, 27 , Px mice had a higher frequency of BrdU incorporation in all pancreatic cells (islets, acini, ducts and blood vessels) than sham-operated mice. This included a 2.6-fold increase in the frequency of BrdU þ b-cells after Px, indicative of b-cell regeneration (12.3% in Px versus 4.8% in shamoperated mice; n ¼ 7,388 and 5,311 b-cells, respectively; Fig. 5a ).
We injected tamoxifen into adult RIP-CreER;Z/AP mice (n ¼ 2), and 4 days later 70% of their pancreas was removed. The mice were killed 2 months after the operation; the remnant of the pancreas, as well as the previously excised and fixed portion, were stained for insulin and HPAP. All islets examined in the remnant portion (n ¼ 126) and in the excised portion (n ¼ 111) contained numerous HPAP þ b-cells, showing that the islets found 2 months after Px existed before the operation. Furthermore, as observed during normal growth and adult life (Fig. 3) , the frequency of clusters (groups of 1-10 b-cells) containing HPAP þ cells in the remnant portion (87.3%, n ¼ 276) was similar to that in the excised portion (85.5%, n ¼ 325), indicating that the clusters might not represent coalescing stem-cell-derived b-cells. These results suggest that, even after Px, no new islets are generated from stem cells. Furthermore, the frequency of HPAP þ b-cells within islets did not decrease after Px (data not shown), arguing against a significant contribution from non-b-cells or stem cells to the b-cells and islets found after pancreatectomy.
We wished to analyse directly the origin of new b-cells after Px, regardless of turnover rates or variations in labelling efficiency. To accomplish this we injected a high dose of tamoxifen (five injections of 8 mg) to another group of RIP-CreER;Z/AP mice (n ¼ 5), and 14 days later performed 70% Px. BrdU was administered continuously for 2 weeks after the operation to label dividing cells, after which the mice were killed and their pancreases triple-stained for BrdU, insulin and HPAP (Fig. 5b) . b-cells born after Px should express insulin and be BrdU ; that is, they would have come from b-cells existing at the time of Px. It is theoretically possible that a putative 'stem cell' directly differentiates into a b-cell without cell division-that is, without BrdU incorporation. However, the absence of HPAP dilution in the chase experiments described above is inconsistent with such a process contributing significantly to b-cell number. This result further suggests that b-cells are derived from b-cells, not from stem cells.
Discussion
We conclude that pre-existing b-cells are the major source for new b-cells during adult life, as well as during regeneration from partial pancreatectomy (Fig. 1a, model 3 ). This conclusion challenges the view that adult stem cells (undifferentiated cells capable of selfrenewal and differentiation) are significant in b-cell homeostasis. Instead, we submit that terminally differentiated b-cells retain a proliferative capacity that can account for turnover and expansion throughout a mouse's life. There are several ways in which our data could be reconciled with previous reports claiming the existence of pancreatic stem cells. First, our experiments cannot prove the absence of stem cells, given the degree of variation in labelling efficiency inherent to the CreER system. It is possible that rare stem or progenitor cells exist but give rise to a small, physiologically unimportant fraction of b-cells 17 . A convincing demonstration of such putative stem cells could be provided by genetic lineage tracing, for example by using a duct cell promoter driving Cre recombinase. Second, it is formally possible that the insulin gene is transcriptionally active in stem cells. If so, these putative stem cells must be unipotent because HPAP þ cells gave rise only to b-cells. Even after a long chase, no other endocrine, exocrine or ductal cells were HPAP þ . In effect, such putative unipotent stem cells would be indistinguishable from b-cells. Third, facultative pancreatic stem cells might exist and be activated in response to specific insults other than pancreatectomy 24, 30 . Fourth, the vast majority of Px and regeneration studies were done with rats rather than mice and it is possible that these species differ in the mode of regeneration. Last, b-cells could transiently dedifferentiate (and possibly acquire stem cell markers) before generating new b-cells 12 . A similar process is thought to occur during angiogenesis, in which differentiated endothelial cells give rise to 'activated endothelium', which then proliferates and organizes into new blood vessels 31 . However, there is currently no evidence for such a mechanism in the pancreas.
It has been suggested that new lobes, including new islets, are constantly generated in the adult pancreas 13, 32 . In contrast, the data presented here support the idea that the number of islets during adult life is fixed, with homeostatic responses (for example, b-cell expansion) being performed by differentiated cells residing in these structural units. Indeed, it was recently reported that average islet size, but not islet density, increases with age [33] [34] [35] . Our studies indicate that there is a time during embryonic development, or early postnatal life, at which the number of islets is set. The data also indicate that b-cell formation from undifferentiated precursors ceases at this time in that new b-cells that form subsequently come from pre-existing b-cells. Further experiments are required to determine when this switch occurs.
Our results emphasize the importance of using direct lineage tracing, rather than histological snapshots, to determine a cell of origin or the provenance of a given tissue. The method presented here can be adapted to assess the contribution of stem cells in other organs during growth, normal turnover and regeneration. In addition, it could be used to determine the cell of origin in cancer models.
One implication of this study concerns possible cell-based therapies for type I diabetes, in which b-cells are destroyed by an autoimmune attack. It points to the significant proliferative potential of differentiated b-cells in vivo, a capacity that might be exploited for expansion to a clinically useful mass. In addition, the results highlight the fact that embryonic stem cells are currently the only type of stem cell that is unquestionably capable of differentiation into b-cells. A
Methods

Mice
Z/AP reporter mice were a gift from C. Lobe 18 . The RIP-CreER construct was generated by fusing a 0.66-kilobase SmaI-HindIII fragment of the RIP2 promoter 15 to a minimal hsp68 promoter (a gift from M. Gannon 36 ), and placing the chimaeric promoter upstream of CreER (a gift from A. McMahon 16 ). Transgenic mice were created by injection of the construct into the pronucleus. Three founders were identified that, when crossed with Z/AP, showed b-cell-specific expression of HPAP (defined by immunohistochemical co-localization of HPAP and insulin). For this study we used two lines that showed efficient recombination. Both lines showed tamoxifen-dependent expression of HPAP. By 10 months of age, double transgenic mice that did not receive tamoxifen had occasionally one to five HPAP þ cells per islet, reflecting the cumulative lifetime leakage of the system. RIP-CreER;Z/AP double transgenic mice were generated by crossing single heterozygous transgenics. Tamoxifen (Sigma) was dissolved in corn oil at 20 mg ml 21 and injected intraperitoneally or subcutaneously twice a week. RIP-CreER;Z/AP mice treated with tamoxifen remained euglycaemic and had normal pancreatic histology, indicating that tamoxifen injection, Cre-mediated recombination and HPAP expression had no adverse effects. For continuous labelling of dividing cells, BrdU (Sigma) was given in the drinking water at 0.8 mg ml 21 , and the water was changed every other day.
Analysis
Formalin-fixed, paraffin-embedded 6-mm sections of the pancreas were used. We identified b-cells by immunostaining for insulin (guinea-pig anti-insulin (Dako), dilution 1:500) or for pdx1 (guinea-pig anti-pdx1 (a gift from C. Wright), dilution 1:500). Other pancreatic cell types were identified with the following antibodies: guinea-pig antiglucagon (Linco; dilution 1:200), sheep anti-somatostatin (ARP; dilution 1:200), guinea-pig anti-pancreatic polypeptide (Linco; dilution 1:200) and rabbit anti-amylase (Sigma; dilution 1:200). Ducts were labelled with biotinylated DBA lectin (vector; dilution 1:200). HPAP þ cells were identified by incubating slides with alkaline phosphatase substrate as described 17, 18 or by immunostaining (rabbit anti-HPAP (Zymed), dilution 1:100, or goat anti-HPAP (Santa Cruz), dilution 1:100). BrdU þ cells were stained with biotinylated anti-BrdU antibodies (BrdU in-situ detection kit (Becton Dickinson), dilution 1:100). For both HPAP and BrdU immunostaining we performed antigen retrieval (Retrievagen A; Becton Dickinson) before incubation with primary antibody. Secondary antibodies conjugated with horseradish peroxidase, fluorescein isothiocyanate, rhodamine (Jackson) or CY5 (Molecular Probes) were used at 1:200 dilution. Flow cytometry was carried out with MoFlo (Cytomation). Pancreases were dissociated to a single-cell suspension essentially as described 37, 38 and cells were stained with guinea-pig anti-insulin antibody followed by a CY5-conjugated anti-guinea-pig antibody.
